Full Breakdown
Study Suggests Carbon Monoxide May Explain Lower Parkinson’s Risk Among Smokers
By Drooid · · How we work
Core Findings
A large observational study published in *JAMA Neurology* on September 8 reported that individuals with higher exhaled carbon monoxide (CO) levels—whether smokers or non-smokers—had about a 30 percent lower risk of developing Parkinson’s disease. The dose-related effect was most pronounced among never-smokers whose breath contained 3 parts per million (ppm) CO or more. Researchers concluded that the protective association previously observed with tobacco use might be driven by CO rather than nicotine or other tobacco constituents.
Historical Context
Epidemiological work over the past two decades has consistently shown an inverse relationship between cigarette smoking and Parkinson’s disease incidence. A 2020 British-doctor cohort followed participants for 65 years and found smokers experienced a 30-40 percent reduced risk compared with never-smokers. Earlier investigations, including a 2002 twin study and a 2005 analysis of smokeless-tobacco users, reported similar patterns, prompting speculation that some component of tobacco could be neuroprotective.
Study Design and Statistics
The new analysis incorporated data from more than 500,000 participants across the United Kingdom and China. Researchers measured exhaled CO using standard breath-testing devices and tracked Parkinson’s diagnoses over several years. Participants with CO readings of >=3 ppm exhibited roughly a 30 percent lower incidence of Parkinson’s disease than those with lower readings. The association persisted after adjusting for age, sex, smoking status, and known environmental exposures.
Expert Interpretation
Dr. Michael Okun, a neurology professor at the University of Florida, emphasized that CO is a known signaling molecule produced in small amounts by the human body. He noted that low-level CO may modulate oxidative stress, inflammation, and cell-survival pathways, potentially safeguarding dopamine-producing neurons. Okun described the finding as “eye-opening” but cautioned that it does not prove CO prevents Parkinson’s disease; rather, it offers a specific biological clue for further investigation.
Dr. Alberto Ascherio, a Harvard Medical School professor of medicine who participated in earlier tobacco-related research, suggested that other tobacco constituents—such as monoamine-oxidase B (MAO-B) inhibitors—might also contribute to the observed risk reduction. He acknowledged that the exact protective compounds remain unidentified and that the current CO evidence does not rule out additional mechanisms.
Remaining Uncertainties
The study’s observational nature precludes definitive statements about causality. While the CO-Parkinson’s link is statistically robust, researchers have not demonstrated that experimentally administered CO would confer protection, nor have they ruled out residual confounding from unmeasured lifestyle factors. Moreover, the health hazards of CO exposure at higher concentrations remain well documented, and public-health agencies continue to warn against smoking due to its proven role in cancer, cardiovascular disease, and mortality.
Future work will need to isolate CO’s effects from other tobacco-related chemicals, explore dose-response relationships in controlled settings, and assess whether CO-based therapeutics can be developed without incurring toxicity. Until such data emerge, the association should be viewed as a promising lead rather than a basis for clinical recommendation.